Wells Fargo’s Clovis Oncology, Inc. CLVS Stock Holding History

Wells Fargo’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-80,284	Closed	-$96K	–	7869
2022 Q3	$96K	Buy	80,284 +32,546	+68%	+$50.7K	﹤0.01%	4624
2022 Q2	$86K	Sell	47,738 -58,148	-55%	-$85.8K	﹤0.01%	4727
2022 Q1	$214K	Sell	105,886 -52,629	-33%	-$103K	﹤0.01%	4939
2021 Q4	$430K	Sell	158,515 -29,527	-16%	-$109K	﹤0.01%	4781
2021 Q3	$839K	Buy	188,042 +10,897	+6%	+$52.5K	﹤0.01%	4356
2021 Q2	$1.03M	Buy	177,145 +64,372	+57%	+$377K	﹤0.01%	4198
2021 Q1	$791K	Sell	112,773 -133,753	-54%	-$897K	﹤0.01%	4411
2020 Q4	$1.18M	Buy	246,526 +38,498	+19%	+$195K	﹤0.01%	3906
2020 Q3	$1.21M	Sell	208,028 -6,679	-3%	-$40K	﹤0.01%	3707
2020 Q2	$1.45M	Buy	214,707 +139,566	+186%	+$1.06M	﹤0.01%	3531
2020 Q1	$479K	Sell	75,141 -6,027	-7%	-$48.3K	﹤0.01%	4063
2019 Q4	$846K	Buy	81,168 +22,931	+39%	+$167K	﹤0.01%	3971
2019 Q3	$229K	Buy	58,237 +7,129	+14%	+$57.7K	﹤0.01%	4879
2019 Q2	$760K	Buy	51,108 +5,300	+12%	+$95.8K	﹤0.01%	4088
2019 Q1	$1.14M	Buy	45,808 +12,148	+36%	+$305K	﹤0.01%	3782
2018 Q4	$605K	Buy	33,660 +4,583	+16%	+$93.6K	﹤0.01%	4217
2018 Q3	$853K	Sell	29,077 -133,209	-82%	-$5.16M	﹤0.01%	4072
2018 Q2	$7.38M	Sell	162,286 -59,974	-27%	-$2.92M	﹤0.01%	2321
2018 Q1	$11.7M	Sell	222,260 -38,332	-15%	-$2.24M	﹤0.01%	1873
2017 Q4	$17.7M	Sell	260,592 -12,502	-5%	-$874K	0.01%	1538
2017 Q3	$22.5M	Buy	273,094 +40,824	+18%	+$3.24M	0.01%	1337
2017 Q2	$21.7M	Sell	232,270 -44,628	-16%	-$2.73M	0.01%	1337
2017 Q1	$17.6M	Buy	276,898 +236,355	+583%	+$14.4M	0.01%	1459
2016 Q4	$1.8M	Buy	40,543 +22,311	+122%	+$785K	﹤0.01%	3242
2016 Q3	$658K	Buy	18,232 +3,195	+21%	+$68.5K	﹤0.01%	3793
2016 Q2	$206K	Buy	15,037 +2,681	+22%	+$39.2K	﹤0.01%	4396
2016 Q1	$237K	Sell	12,356 -3,321	-21%	-$70.3K	﹤0.01%	4302
2015 Q4	$549K	Sell	15,677 -619,897	-98%	-$40M	﹤0.01%	3862
2015 Q3	$58.4M	Buy	635,574 +606,464	+2,083%	+$52.5M	0.02%	681
2015 Q2	$2.56M	Buy	29,110 +2,514	+9%	+$215K	﹤0.01%	2908
2015 Q1	$1.98M	Buy	26,596 +15,759	+145%	+$1.11M	﹤0.01%	3050
2014 Q4	$607K	Buy	10,837 +1,859	+21%	+$97.7K	﹤0.01%	3837
2014 Q3	$407K	Sell	8,978 -5,010	-36%	-$209K	﹤0.01%	4008
2014 Q2	$579K	Sell	13,988 -4,705	-25%	-$242K	﹤0.01%	3850
2014 Q1	$1.29M	Buy	18,693 +6,601	+55%	+$485K	﹤0.01%	3287
2013 Q4	$728K	Buy	12,092 +652	+6%	+$35.5K	﹤0.01%	3609
2013 Q3	$695K	Sell	11,440 -1,384	-11%	-$98.2K	﹤0.01%	3574
2013 Q2	$859K	Buy	+12,824	New	+$577K	﹤0.01%	3362

Other funds holding CLVS

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Wells Fargo's CLVS Position: Q4 2022 in Review

Wells Fargo sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 80,284 shares — an estimated $96K sold.

Wells Fargo first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $58.4M in Q3 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Wells Fargo reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Wells Fargo sold 80,284 Clovis Oncology, Inc. shares in Q4 2022, an estimated $96K.
Wells Fargo first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
Wells Fargo's Clovis Oncology, Inc. position peaked at $58.4M in Q3 2015.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Wells Fargo's 13F filing for Q4 2022, filed 13 Feb 2023.